Technetium-99m labeled Ibuprofen: Development and biological evaluation using sterile inflammation induced animal models

Khan, Naeem-Ul-Haq; Naqvi, Syed Ali Raza; Sohail, Hamza; Roohi, Samina; Jamal, Muhammad Asghar

doi:10.1007/s11033-019-04762-2

Cited by 9 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stannous chloride also facilitated radiolabeling reactions. 22,23 In this study, the effect of stannous chloride on the radiolabeling process was examined, and ideal stannous chloride amount was found to be 500 μg. The radiochemical purity of [ 99m Tc]-TcIMT with 500 μg/mL stannous chloride solution was over 90% and did not change significantly for 6 h at room temperature (p > 0.05) (Figure 6).…”

Section: ■ Resultsmentioning

confidence: 98%

Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate

et al. 2020

View full text Add to dashboard Cite

Section: ■ Resultsmentioning

confidence: 98%

Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate

et al. 2020

View full text Add to dashboard Cite

“…There are many studies in the synthesis of 99m Tc radiopharmaceuticals using stannous chloride as a reducing agent, because it has good reducing power and is non-toxic. In addition, stannous chloride effectively facilitates the reaction during the radiolabeling process [17][18] . The reaction of decreasing the valence number of 99m Tc with the reducing agent SnCl 2 can be explained by the following reaction 19 .…”

Section: Resultsmentioning

confidence: 99%

99mTc labeled genistein kits: development methods and quality control for breast cancer radiotracer applications

Ramdhani

Sriy

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective. Selective estrogen receptor modulators (SERMs) have been widely used to treat breast cancer, osteoporosis, and postmenopausal symptoms. SERMs have an affinity for estrogen receptors (ER) in target tissues and resist stimulation of the breast, bone, and endometrium. Genistein as an isoflavone compound that has a high affinity for ERβ targets makes it a potential target or prognostic marker for breast cancer. This study was carried out to develop 99mTc-genistein kit that can be used to detect breast cancer. Methods. The synthesis process and quality control were investigated to obtain the optimal formula for the ratio of a substance, reducing agent, optimal conditions of the synthesis reaction, physicochemical properties of the kit, and its stability to meet the requirements of radiochemical purity. Results. The radiochemical purity in the development of the radiopharmaceutical kit was 93.25% ± 0.30%. The physicochemical properties of the kit preparations showed hydrophilic properties, good plasma protein binding, no electrical charge, and were stable at storage temperatures. Conclusions. The radiochemical purity of the radiopharmaceutical kits meets the requirements of the United State Pharmacopeia and has good physicochemical properties to be developed into kits.

show abstract

“…Radiolabeling studies: Different amounts of reducing agent, different radioactivity doses, pH values and incubation times were used to test the radiolabeling of 99m Tc-exendin-4. The radiochemical purity (RP) of the samples was measured using radio thin layer chromatography (RTLC) [26][27][28].…”

Section: Methodsmentioning

confidence: 99%

99mTc-exendin-4: Radiolabeling and quality control studies of glucagon-like peptide analog

İlem-Özdemir¹,

Ekinci²,

Özgenç³

et al. 2022

j-ebr

View full text Add to dashboard Cite

Technetium-99m labeled Ibuprofen: Development and biological evaluation using sterile inflammation induced animal models

Cited by 9 publications

References 19 publications

Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate

Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate

99mTc labeled genistein kits: development methods and quality control for breast cancer radiotracer applications

99mTc-exendin-4: Radiolabeling and quality control studies of glucagon-like peptide analog

Contact Info

Product

Resources

About